Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis

Mythily Srinivasan, Don Jon Summerlin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBD) result from dysregulated immune responses to the luminal antigens initiated by the colonic epithelial cells (CEC) and propagated by activated CD4+ T cells. Biological therapies are being developed that suppress inflammation and promote epithelial homeostasis. Treatment with the CD80-competitive antagonist peptide (CD80-CAP) has been shown to suppress T cell responses in multiple disease models. Here we investigated the effect of the CD80-CAP on the CEC responses in experimental colitis. Balb/c mice induced with trinitrobenzene sulfonic acid (TNBS) colitis were administered CD80-CAP/control peptide/vehicle. Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. Furthermore, the CD80-CAP treatment suppressed Th1cytokines and enhanced Th2 responses by the CEC in colitis mice. In conclusion, CD80-CAP administration ameliorated TNBS colitis by reducing the inflammatory cell infiltration and modulating the CEC response potentially restoring mucosal tolerance.

Original languageEnglish (US)
Pages (from-to)411-421
Number of pages11
JournalClinical Immunology
Volume133
Issue number3
DOIs
StatePublished - Dec 2009

Fingerprint

Trinitrobenzenes
Sulfonic Acids
Colitis
Epithelial Cells
Inflammation
T-Lymphocytes
Biological Therapy
Inflammatory Bowel Diseases
CD80-CAP
Homeostasis
Antigens
Messenger RNA
Peptides
Therapeutics

Keywords

  • Apoptosis
  • CD80 blockade
  • Colitis
  • Intestinal epithelial cells
  • Toll-like receptors

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis. / Srinivasan, Mythily; Summerlin, Don Jon.

In: Clinical Immunology, Vol. 133, No. 3, 12.2009, p. 411-421.

Research output: Contribution to journalArticle

@article{6beeee8b8ac04750bbb19aac5c62c10e,
title = "Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis",
abstract = "Inflammatory bowel diseases (IBD) result from dysregulated immune responses to the luminal antigens initiated by the colonic epithelial cells (CEC) and propagated by activated CD4+ T cells. Biological therapies are being developed that suppress inflammation and promote epithelial homeostasis. Treatment with the CD80-competitive antagonist peptide (CD80-CAP) has been shown to suppress T cell responses in multiple disease models. Here we investigated the effect of the CD80-CAP on the CEC responses in experimental colitis. Balb/c mice induced with trinitrobenzene sulfonic acid (TNBS) colitis were administered CD80-CAP/control peptide/vehicle. Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. Furthermore, the CD80-CAP treatment suppressed Th1cytokines and enhanced Th2 responses by the CEC in colitis mice. In conclusion, CD80-CAP administration ameliorated TNBS colitis by reducing the inflammatory cell infiltration and modulating the CEC response potentially restoring mucosal tolerance.",
keywords = "Apoptosis, CD80 blockade, Colitis, Intestinal epithelial cells, Toll-like receptors",
author = "Mythily Srinivasan and Summerlin, {Don Jon}",
year = "2009",
month = "12",
doi = "10.1016/j.clim.2009.09.001",
language = "English (US)",
volume = "133",
pages = "411--421",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis

AU - Srinivasan, Mythily

AU - Summerlin, Don Jon

PY - 2009/12

Y1 - 2009/12

N2 - Inflammatory bowel diseases (IBD) result from dysregulated immune responses to the luminal antigens initiated by the colonic epithelial cells (CEC) and propagated by activated CD4+ T cells. Biological therapies are being developed that suppress inflammation and promote epithelial homeostasis. Treatment with the CD80-competitive antagonist peptide (CD80-CAP) has been shown to suppress T cell responses in multiple disease models. Here we investigated the effect of the CD80-CAP on the CEC responses in experimental colitis. Balb/c mice induced with trinitrobenzene sulfonic acid (TNBS) colitis were administered CD80-CAP/control peptide/vehicle. Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. Furthermore, the CD80-CAP treatment suppressed Th1cytokines and enhanced Th2 responses by the CEC in colitis mice. In conclusion, CD80-CAP administration ameliorated TNBS colitis by reducing the inflammatory cell infiltration and modulating the CEC response potentially restoring mucosal tolerance.

AB - Inflammatory bowel diseases (IBD) result from dysregulated immune responses to the luminal antigens initiated by the colonic epithelial cells (CEC) and propagated by activated CD4+ T cells. Biological therapies are being developed that suppress inflammation and promote epithelial homeostasis. Treatment with the CD80-competitive antagonist peptide (CD80-CAP) has been shown to suppress T cell responses in multiple disease models. Here we investigated the effect of the CD80-CAP on the CEC responses in experimental colitis. Balb/c mice induced with trinitrobenzene sulfonic acid (TNBS) colitis were administered CD80-CAP/control peptide/vehicle. Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. Furthermore, the CD80-CAP treatment suppressed Th1cytokines and enhanced Th2 responses by the CEC in colitis mice. In conclusion, CD80-CAP administration ameliorated TNBS colitis by reducing the inflammatory cell infiltration and modulating the CEC response potentially restoring mucosal tolerance.

KW - Apoptosis

KW - CD80 blockade

KW - Colitis

KW - Intestinal epithelial cells

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=70350596212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350596212&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2009.09.001

DO - 10.1016/j.clim.2009.09.001

M3 - Article

VL - 133

SP - 411

EP - 421

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -